
GlobeNewswire · 2026-10-27 10:00 UTC
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - GNW
Loading the story on Tree News…

GlobeNewswire · 2026-10-27 10:00 UTC
Loading the story on Tree News…